SCHEMBL5137546

SCHEMBL5137546

CCCCn1c(CN(CCc2cc(OC)ccc2OC)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 10/20 0.49
HTR2B P41595 10/20 0.49
HTR2C P28335 9/20 0.49
C5AR1 P21730 1/20 0.49
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
ADRB1 P08588 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
DRD2 P14416 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
DRD1 P21728 1/20 0.43
DRD4 P21917 1/20 0.43
SLC6A2 P23975 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR1D P28221 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134933 0.94 C5AR1 (0.49) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5137323 0.94 C5AR1 (0.51) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5136286 0.93 HTR2A (0.48) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5135478 0.92 C5AR1 (0.48) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5136131 0.92 C5AR1 (0.52) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5137845 0.90 HTR2A (0.54) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5137544 0.89 HSP90AA1 (0.39)
SCHEMBL5136237 0.88 C5AR1 (0.55) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5137371 0.88 C5AR1 (0.49) HTR2AHTR2BHTR2CC5AR1TP53
SCHEMBL5137595 0.88 TP53 (0.55) HTR2AHTR2BHTR2CC5AR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed